Synthetic Lethality Triggered by Combining Olaparib with BRCA2–Rad51 Disruptors
ACS Chemical Biology2017Vol. 12(10), pp. 2491–2497
Citations Over TimeTop 25% of 2017 papers
Federico Falchi, Elisa Giacomini, Tiziana Masini, Nicolas Boutard, Lorenza Di Ianni, Marcella Manerba, Fulvia Farabegoli, Lara Rossini, Janet Robertson, Saverio Minucci, Isabella Pallavicini, Giuseppina Di Stefano, Marinella Roberti, Roberto Pellicciari, Andrea Cavalli
Abstract
In BRCA2-defective cells, poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors can trigger synthetic lethality, as two independent DNA-repairing mechanisms are simultaneously impaired. Here, we have pharmacologically induced synthetic lethality, which was triggered by combining two different small organic molecules. When administered with a BRCA2-Rad51 disruptor in nonmutant cells, Olaparib showed anticancer activity comparable to that shown when administered alone in BRCA2-defective cells. This strategy could represent an innovative approach to anticancer drug discovery and could be extended to other synthetic lethality pathways.
Related Papers
- → Development of synthetic lethality in cancer: molecular and cellular classification(2020)109 cited
- → Synthetic Lethality Triggered by Combining Olaparib with BRCA2–Rad51 Disruptors(2017)40 cited
- → Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss(2017)1 cited
- Comprehensive analysis and prediction of synthetic lethality using subcellular locations.(2005)
- → Biological analysis of the in-vitro effects of homologous recombination inhibition and its use in cancer treatment through synthetic lethality(2021)